INDERAL LA (propranolol hydrochloride) by ANI Pharmaceuticals is clinical pharmacology general propranolol is a nonselective, beta-adrenergic receptor-blocking agent possessing no other autonomic nervous system activity. First approved in 1983.
Drug data last refreshed 7h ago · AI intelligence enriched 4d ago
INDERAL LA (propranolol hydrochloride) is a nonselective beta-adrenergic receptor-blocking agent in extended-release capsule form, approved since 1983 for oral use. It treats hypertension, angina pectoris, and cardiac arrhythmias by competitively blocking beta-receptor sites and reducing cardiac output, heart rate, and oxygen demand. The extended-release formulation provides 24-hour efficacy with once-daily dosing, though blood levels are lower than conventional propranolol dosed multiple times daily.
Mature product approaching loss of exclusivity with modest Part D spending signals a contracting brand team focused on maintaining market share against generics.
CLINICAL PHARMACOLOGY General Propranolol is a nonselective, beta-adrenergic receptor-blocking agent possessing no other autonomic nervous system activity. It specifically competes with beta-adrenergic receptor-stimulating agents for available receptor sites. When access to beta-receptor sites is…
Worked on INDERAL LA at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer
Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg
Food Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on INDERAL LA offers limited growth opportunities given LOE-approaching lifecycle and minimal linked job openings, but provides valuable experience in defensive strategy, generic transition management, and mature-product optimization. Roles emphasize payer negotiations, cost-effectiveness messaging, and physician education rather than new product launches.